ML-007C-MA is being developed by MapLight Therapeutics as a treatment for hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The market for Alzheimer's-related psychosis treatments is significant, given the increasing prevalence of Alzheimer's disease globally. The competitive landscape includes existing therapies and emerging candidates targeting similar indications. Successful outcomes in this trial could position ML-007C-MA favorably within this market, particularly if it demonstrates superior safety and tolerability profiles compared to current options. Diligence implications include assessing the robustness of the antecedent study (ML-007C-MA-221) and the potential for regulatory hurdles given the patient population's vulnerability.